Racing Bayer, Astellas puts the final PhIII slide into its FDA/EMA pitch
Coming up on the 5th anniversary of its $870 million deal to acquire the menopause drug fezolinetant on Phase IIa data, Astellas says its late-stage drug came through in a Phase III safety study, helping to underpin its regulatory filings to come.
According to researchers, the drug cleared the primary hurdle on endometrial health, with the most common adverse events pegged on headaches and Covid infections.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
